BD’s launch will be a test for the utility of COVID-19 antigen testing

The launch and scale-up of BD’s SARS-CoV-2 rapid antigen test will help reveal whether the modality strikes the right balance of speed, accessibility and reliability needed to fill critical holes in COVID-19 testing infrastructure.

Becton Dickinson and Co. (NYSE:BDX) announced Monday it received FDA Emergency Use Authorization (EUA) for its test to detect SARS-CoV-2 nucleocapsid protein antigens on a portable instrument that gives results in 15 minutes. ...